Pleural mesothelioma malignant

6 trials 4 recruiting MedDRA PT
6 Registered trials
4 Recruiting
6 Unique sponsors
10 Unique IMPs
0 Commercial trials
Drug classes (ATC)
L Oncology (ATC L) 4
— ATC code not specified 2
Mechanism of action (INN-stem analysis)
Unknown / small molecule 2 substances
Checkpoint inhibitor (PD-1) 2 substances
Platinum compound 2 substances
Checkpoint inhibitor (CTLA-4) 1 substance
Colony-stimulating factor 1 substance
Antimetabolite 1 substance
Monoclonal antibody (primate) 1 substance
Phase III: 1 Phase II/III: 1 Phase II: 4

Filter these 6 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 6 trials

Phase III

1 trial
  • G.O.I.R.C. Gruppo Oncologico Italiano Di Ricerca Clinica Academic
    IMP not specified
    2024-519286-21-00 1 country 2024 n=90
    Recruiting

Phase II/III

1 trial
  • Oslo University Hospital HF Academic
    ALREFIMOTIDE, RILETAMOTIDE, TAPDERIMOTIDE; IPILIMUMAB; NIVOLUMAB; SARGRAMOSTIM
    2022-502604-67-00 4 countries 2019 n=90
    Ended

Phase II

4 trials
  • Antwerp University Hospital Academic
    CARBOPLATIN; CISPLATIN; IPILIMUMAB; NIVOLUMAB; PEMETREXED
    2023-504302-11-02 1 country 2025 n=37
    Recruiting
  • Centre Hospitalier Universitaire De Nantes Academic
    AMINOLEVULINIC ACID HYDROCHLORIDE; NIVOLUMAB
    2024-514103-33-00 1 country 2022 n=20
    Recruiting
  • Intergroupe Francophone De Cancerologie Thoracique Academic
    IVONESCIMAB
    2024-519052-82-00 1 country 2025 n=38
    Recruiting
  • Istituto Oncologico Veneto Academic
    PEMBROLIZUMAB
    2023-509584-24-01 1 country 2024 n=40
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Oslo University Hospital HF Academic 1 Phase II/III 0
Antwerp University Hospital Academic 1 Phase II 1
Centre Hospitalier Universitaire De Nantes Academic 1 Phase II 1
Intergroupe Francophone De Cancerologie Thoracique Academic 1 Phase II 1
Istituto Oncologico Veneto Academic 1 Phase II 0
G.O.I.R.C. Gruppo Oncologico Italiano Di Ricerca Clinica Academic 1 Phase III 1
New trials by year
2019
1
2022
1
2024
2
2025
2
← All indication landscapes